Trulicity (Dulaglutide) Employer and ICHRA Coverage: A Woman's Complete Navigation Guide

What Trulicity Actually Costs Without Coverage

The sticker price is painful. A four-pen box of Trulicity (covering one month at any dose) had a list price of approximately $970 as of late 2024, and prices have continued to rise. Most women paying cash spend between $900 and $975 per month depending on pharmacy and dose. At the 1.5 mg dose, the cost is identical to the 0.75 mg starting dose because both come in a four-pen carton at the same list price.

That number is not what most commercially insured women actually pay. The gap between list and out-of-pocket depends entirely on your plan's formulary placement, your deductible status, and which savings programs you layer on top.

Why the Price Varies So Much by Pharmacy

Pharmacy benefit managers negotiate different rebates with Eli Lilly, so your out-of-pocket at a large chain can differ by $200 or more from an independent pharmacy or a mail-order supplier. Running a GoodRx check before filling is worth the two minutes; GoodRx coupons are not combinable with insurance but are sometimes cheaper than your copay if your plan places dulaglutide on a non-preferred tier.

The Formulary Tier Problem

Most large employer plans place GLP-1 receptor agonists on Tier 3 or Tier 4. Tier 3 specialty copays average $60 to $100 per month with insurance, but that assumes you have met your deductible. Before deductible, you may owe the full negotiated rate, which can still exceed $600 per fill.

How Employer Health Plans Cover Trulicity in 2026

Your employer plan covers Trulicity based on its pharmacy benefit formulary, its medical necessity criteria, and whether your employer has added a separate GLP-1 carve-out policy. These three factors move independently of each other.

Understanding the Prior Authorization Process

Almost every commercial plan requires prior authorization (PA) for Trulicity. The PA criteria your insurer uses almost always include:

• A confirmed diagnosis of type 2 diabetes (ICD-10 E11.x)
• Documentation that metformin was tried and either failed or was not tolerated
• An HbA1c above a plan-specific threshold (commonly 7.5% or higher)
• Sometimes, a BMI above a specified cutoff

Women with polycystic ovary syndrome (PCOS) and insulin resistance frequently do not meet the type 2 diabetes criterion even when they have significant metabolic disease. If your prescriber is ordering Trulicity primarily for PCOS-related insulin resistance or weight, you should discuss whether your HbA1c, fasting insulin, and glucose tolerance results can support a diabetes or prediabetes code, because coverage under a pure PCOS or obesity indication is far less consistent.

What to Do When Prior Authorization Is Denied

A denial is not a final answer. The standard sequence is:

1. Ask your prescriber to submit a peer-to-peer review within 24 to 72 hours of the denial.
2. File a formal internal appeal, citing your specific lab values.
3. If the internal appeal fails, request an external independent review, which is a legal right under the ACA for most employer-sponsored plans.
4. Simultaneously activate whatever patient assistance or savings program Lilly offers (see the section below) so you are not going without medication during the appeal.

The ACA external review process applies to non-grandfathered group health plans, which covers most employer-sponsored plans established after 2010.

GLP-1 Carve-Outs: A 2025 to 2026 Trend You Need to Know

A significant number of large employers added explicit GLP-1 exclusions or separate obesity-drug carve-outs between 2024 and 2026, citing cost. A 2024 KFF Employer Health Benefits Survey found that only 18% of large employers covered GLP-1 drugs for weight loss, though coverage for diabetes was much higher. If your plan has a GLP-1 carve-out, confirm whether it applies to the diabetes indication specifically, or to all GLP-1 drugs regardless of indication. The wording matters enormously for your PA strategy.

ICHRA and Trulicity: What You Can and Cannot Pay For

An Individual Coverage Health Reimbursement Arrangement (ICHRA) is an employer-funded account that reimburses you for qualifying individual health insurance premiums and, depending on the plan design, out-of-pocket medical expenses. Trulicity intersects with ICHRA in two distinct ways.

Using ICHRA Funds to Pay Premiums for a Plan That Covers Trulicity

If your employer offers an ICHRA instead of a group plan, you select your own individual market insurance policy. ICHRA participants can use their employer funds to reimburse any ACA-qualified individual health plan premium. This means you can shop for an individual plan that places Trulicity on a more favorable formulary tier than whatever your previous employer group plan offered.

Before selecting your individual plan on healthcare.gov or your state exchange, run a formulary check:

• Search for dulaglutide (the generic name) in the plan's drug list.
• Confirm whether PA is required and what the criteria are.
• Compare Tier 3 specialty copays across plan options at your income level.

Using ICHRA Funds for Out-of-Pocket Drug Costs

Some ICHRA plan designs permit reimbursement of out-of-pocket medical expenses beyond premiums, called "excepted benefits" or "integrated" ICHRA designs. If yours does, your Trulicity copays and deductible amounts may be reimbursable. IRS Notice 2019-45 outlines what qualifies; prescription drugs for a diagnosed condition qualify under the standard definition.

The ICHRA Trulicity decision framework for women in 2026:

| Your situation | Best ICHRA strategy | |---|---| | Diagnosed type 2 diabetes, stable coverage | Use ICHRA funds to stay on a plan with Tier 2 or 3 GLP-1 coverage | | PCOS with insulin resistance, no diabetes diagnosis | Prioritize plans with broader metabolic or "prediabetes" formulary criteria; layer Lilly savings card | | Perimenopause with new-onset insulin resistance | Discuss whether a new HbA1c or OGTT supports a diabetes/prediabetes code before choosing a plan | | Trying to conceive | Trulicity must be stopped before conception; coverage continuity matters for the transition drug |

HSA and FSA: Using Tax-Advantaged Dollars for Trulicity

Yes, you can use HSA and FSA funds for Trulicity. Prescription medications are eligible medical expenses under IRS Publication 502, and Trulicity is a prescription drug dispensed with a valid prescription. There are no GLP-1-specific exclusions in IRS guidance.

HSA Advantages for Women on Long-Term GLP-1 Therapy

A Health Savings Account is particularly valuable if you expect to be on Trulicity for years, as is common in type 2 diabetes management. The 2025 HSA contribution limit is $4,300 for self-only coverage and $8,550 for family coverage. Because unused HSA dollars roll over indefinitely, women who are currently healthy can bank contributions now and draw on them during a high-cost treatment phase, including during perimenopause when metabolic needs often shift.

FSA Rules: Use It or You Lose It

Flexible Spending Accounts have the same IRS eligibility rules but do not roll over (beyond a small grace period or $640 rollover allowed in 2025). If you know you will be on Trulicity for the full plan year, you can elect up to $3,300 in an FSA for 2025 and apply that to your copays dollar-for-dollar, reducing your taxable income by the same amount.

Practical Tip: Timing Your FSA Election With Your Deductible Reset

Most employer plans reset deductibles on January 1. If your Trulicity costs are highest in January through March (before you hit your deductible), front-load FSA use in those months. Because FSA funds are available on day one of the plan year regardless of how much you have contributed, you can pay a $600 fill in January with FSA funds and then spread the contribution across the remaining payroll periods.

Lilly's Savings Programs: Savings Card, Patient Assistance, and Insulin Value Program

Eli Lilly offers several programs that can run alongside, or instead of, insurance coverage. Programs change frequently; verify current terms directly at Lilly's patient support page.

Lilly Savings Card (Commercially Insured Patients)

For women with commercial insurance (including most employer plans and individual market plans), the Lilly Savings Card can reduce monthly out-of-pocket Trulicity costs to as low as $25 per month, subject to eligibility. As of 2026:

• You must have commercial insurance (Medicare, Medicaid, and TRICARE are excluded).
• The card applies after your insurance pays its portion.
• Annual savings caps apply; confirm the current cap before relying on this for full-year planning.

Women on an ICHRA-funded individual market plan qualify for the savings card as long as their individual plan is commercial rather than a public program.

Lilly Cares Foundation (Uninsured or Underinsured)

If you have no insurance or your plan explicitly excludes Trulicity, the Lilly Cares Foundation provides the drug at no cost to eligible patients. Income eligibility thresholds are set at a multiple of the federal poverty level; these thresholds change annually.

Lilly's InsulinValue.com and the $35 Cap History

Trulicity is not insulin, so it does not fall under Lilly's $35 insulin cap program. Do not confuse the two programs when planning.

Sex-Specific Pharmacology: Why Trulicity Works Differently in Women

Women are not simply smaller men, and GLP-1 receptor agonist pharmacokinetics reflect that reality.

Pharmacokinetic Differences by Sex

Dulaglutide is administered subcutaneously and reaches peak concentration (Cmax) in approximately 48 hours. Body composition, fat distribution, and lean mass all influence volume of distribution. Women generally have higher body fat percentage at any given BMI, which can affect drug distribution and potentially the duration of exposure. The Trulicity prescribing information notes that body weight affects exposure, with lower-weight individuals showing higher dulaglutide exposure per dose. Because women on average weigh less and have different fat-to-lean ratios than men, GI side effects (nausea, vomiting, delayed gastric emptying) may present more intensely early in treatment.

How the Menstrual Cycle Interacts With GLP-1 Effects

Insulin sensitivity fluctuates across the menstrual cycle. In the luteal phase (days 15 to 28), progesterone rises and insulin resistance increases, meaning blood glucose may run higher despite the same Trulicity dose. A 2022 review in Diabetes Care confirmed that insulin requirements increase 10 to 25% in the luteal phase in women with type 1 diabetes, and while direct dulaglutide-specific cycle data are limited (a known evidence gap), the same hormonal mechanism applies.

If you notice your blood glucose is harder to control in the two weeks before your period, that is not a Trulicity failure. Document the pattern for your prescriber.

Perimenopause, Insulin Resistance, and Trulicity

The menopause transition is a metabolic inflection point. Estrogen has direct insulin-sensitizing effects; as estrogen declines in perimenopause, fasting insulin rises and visceral fat accumulates even without major weight change. The SWAN study found that insulin resistance increased significantly across the menopausal transition independent of weight gain. Women who previously managed blood glucose adequately on metformin alone may find they need intensification, and Trulicity is one option at that transition. From a coverage standpoint, a new HbA1c drawn at this stage may cross the PA threshold for the first time, opening insurance access that was not available earlier.

PCOS and the GLP-1 Evidence Base

PCOS affects approximately 1 in 10 women of reproductive age and is the most common endocrine disorder in that population. Insulin resistance is present in 50 to 70% of women with PCOS regardless of BMI. GLP-1 receptor agonists reduce fasting insulin, improve ovulatory frequency, and reduce androgen levels in PCOS, though most trial data involve liraglutide and semaglutide rather than dulaglutide specifically. The REWIND trial of dulaglutide enrolled 9,901 participants, 46% of whom were women, but the population had established cardiovascular disease or multiple risk factors and did not include a PCOS subgroup. That is an honest evidence gap: dulaglutide's PCOS-specific data are extrapolated from the GLP-1 class rather than from direct REWIND subgroup analysis.

Pregnancy, Lactation, and Contraception: What Every Woman on Trulicity Needs to Know

Trulicity is contraindicated in pregnancy. This is not a soft caution. Stop dulaglutide before you attempt to conceive.

Animal Data and the Human Evidence Gap

In animal reproduction studies, dulaglutide caused adverse fetal outcomes including reduced fetal weight and skeletal abnormalities at exposures above the human therapeutic dose. The FDA label explicitly states that Trulicity should be discontinued at least two months before a planned pregnancy based on the drug's half-life and the reproductive toxicity signal in animals. Human data on first-trimester dulaglutide exposure are very limited. If you discover you are pregnant while taking Trulicity, stop the medication immediately and contact your prescriber and obstetric provider.

Managing Blood Glucose During Pregnancy After Stopping Trulicity

Women with type 2 diabetes who stop a GLP-1 during pregnancy need a transition plan. ACOG Practice Bulletin 190 recommends insulin as the preferred agent for glucose management in pregnant women with preexisting type 2 diabetes, with metformin as an acceptable adjunct. Your prescriber should have this transition protocol in place before you start trying to conceive, not after you see a positive test.

Lactation

Dulaglutide's transfer into breast milk has not been studied in humans. Given the high molecular weight (approximately 63,000 Da), oral bioavailability in an infant is expected to be negligible, but no human lactation data exist. The FDA label advises that the benefits of breastfeeding should be considered against the mother's need for the drug and potential adverse effects on the infant. This is a genuine evidence gap. Discuss the decision with your endocrinologist and lactation consultant individually.

Contraception Requirements

Dulaglutide is not classified as a teratogen in the same category as isotretinoin or valproate, and there are no formal contraception mandates in the US prescribing information. But given the animal reproductive toxicity data and the recommended two-month washout before conception, women of reproductive age who are not planning pregnancy should use reliable contraception while on Trulicity. GLP-1 medications may slow gastric emptying, which could theoretically reduce peak absorption of oral contraceptives, though published pharmacokinetic studies have not shown a clinically meaningful reduction in oral contraceptive efficacy with dulaglutide. Still, if you are concerned, an IUD or implant eliminates any absorption question entirely.

Who This Is Right for and Who Should Look at Other Options

Women Who Are Good Candidates for Trulicity (and for Navigating Employer Coverage to Get It)

• Women with type 2 diabetes who have not reached HbA1c goal on metformin alone
• Women in perimenopause with new or worsening insulin resistance who now meet a diabetes or prediabetes diagnosis threshold
• Women with PCOS, confirmed insulin resistance, and an HbA1c or fasting glucose that supports a diabetes/prediabetes diagnosis for PA purposes
• Women with type 2 diabetes and established cardiovascular risk, where the REWIND trial showed a 12% relative risk reduction in major adverse cardiovascular events
• Women in postmenopause managing metabolic disease who prefer a once-weekly injection over daily oral medications

Women Who Should Discuss Alternative GLP-1 Agents

• Women who want a weight loss indication for PA purposes: semaglutide (Ozempic for diabetes, Wegovy for obesity) has an FDA obesity indication that opens different formulary pathways.
• Women with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome: GLP-1 receptor agonists, including dulaglutide, carry a black-box warning for this risk and are contraindicated.
• Women planning pregnancy in the next two to three months: start the transition conversation now.
• Women whose employer plan explicitly excludes all GLP-1 drugs and who do not qualify for patient assistance programs: the cost burden without any coverage support may not be sustainable.

Step-by-Step: Getting Trulicity Covered Through Your Employer Plan in 2026

This is the practical sequence most women will need to follow.

1. Get your baseline labs documented. HbA1c, fasting glucose, fasting insulin, and a lipid panel create the medical necessity foundation for a PA.
2. Confirm your plan's formulary placement. Call the member services number on your insurance card and ask whether dulaglutide requires PA and what the criteria are. Get it in writing (by secure message or email confirmation).
3. Have your prescriber submit the PA with the right diagnosis codes. An E11.x (type 2 diabetes) code with documentation of metformin trial is the most consistently approved pathway.
4. Activate the Lilly Savings Card on the same day your prescription is sent. Even if you expect coverage, the card provides a backstop while the PA is processing.
5. If denied, appeal within the window. Most plans allow 60 to 180 days for an internal appeal.
6. If your plan has an ICHRA, review your plan documents for out-of-pocket reimbursement language. The ICHRA plan administrator can confirm whether copays are reimbursable under your specific design.
7. Elect FSA or HSA contributions at your next open enrollment to cover the gap-cost months before your deductible is met.

"The most common reason we see prior authorization denials for dulaglutide in women with PCOS is that the PA was submitted under a PCOS or obesity code without supporting diabetes documentation, even when the patient's fasting glucose and HbA1c clearly met criteria," says Maya Okafor, MD, a reproductive endocrinologist and member of the WomanRx clinical editorial board. "Pulling those labs before submission and making sure the diagnosis code reflects the metabolic picture changes the approval rate substantially."

Stacking Savings: A Realistic Monthly Cost Estimate for 2026

The table below shows realistic monthly out-of-pocket estimates after stacking available programs. All figures are approximations based on publicly available program terms as of early 2026; verify current terms before relying on them.

| Coverage scenario | Estimated monthly cost | |---|---| | No insurance, no assistance | $900 to $970 | | No insurance, Lilly Cares (income-eligible) | $0 | | Commercial insurance, Tier 3, post-deductible + Lilly card | $25 to $60 | | Commercial insurance, Tier 3, pre-deductible + Lilly card | $25 (card cap applies) | | ICHRA-funded individual plan, Tier 2, post-deductible | $40 to $80 | | HSA/FSA payment (any scenario) | Saves 22 to 37% in tax value on top of above |

The single most effective combination for most commercially insured women is: PA approval under a diabetes diagnosis + Lilly Savings Card activated + HSA or FSA dollars covering any remaining copay. That combination brings most women to $25 or less per month in direct cash outlay.